The global leukemia therapeutics treatment market is expected to grow at a CAGR of 6.6% during the forecast period (2025–2035). Factors such as the rising prevalence of leukemia, increasing adoption ...

Celgene has today confirmed that it will acquire Juno Therapeutics for $9 billion, and says the move will make it a leader in cell immunotherapy. The price is a significant premium on the $5.5 bn ...

Changes in Blood Cell Production Over the Lifetime Could Impact Leukemia Outcomes Dec. 5, 2024 — The first comprehensive map of the dramatic changes that take place in the blood system over the ...

in patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and idiopathic cytopenia of unknown significance (ICUS). 1 “Neutrophils can promote or suppress tumor growth.

Faiz Anwer, MD, reported receiving personal fees from Celgene, BMS, and Carobou outside the submitted work.

In the U.S., BREYANZI is approved for treating relapsed or refractory large B-cell lymphoma (LBCL) after at least one prior therapy, as well as relapsed or refractory chronic lymphocytic leukemia or ...

BMS plans to separate its R&D into early- and late-stage divisions, with Celgene’s Rupert Vessey earmarked to lead the former and new recruit Samit Hirawat – formerly head of oncology R&D of ...

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...

In the U.S., BREYANZI is approved for treating relapsed or refractory large B-cell lymphoma (LBCL) after at least one prior therapy, as well as relapsed or refractory chronic lymphocytic leukemia ...